Skip to main content

Advertisement

SpringerLink
Log in

Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Peritoneal carcinomatosis of colorectal cancer origin is associated with poor prognosis. With regard to ovarian, gastric, and pancreatic cancer, the safety and efficacy of intraperitoneal administration of paclitaxel (ip PTX) has been demonstrated. This drug can be administered easily and repeatedly through a catheter into the peritoneal cavity. In this phase I study, we evaluated the safety of ip PTX combined with 5-fluorouracil, folinic acid, oxaliplatin, and bevacizumab (mFOLFOX6-bevacizumab) or capecitabine, oxaliplatin, and bevacizumab (CapeOX-bevacizumab) for colorectal cancer with peritoneal metastasis.

Methods

Colorectal cancer patients with histologically confirmed peritoneal carcinomatosis were enrolled. After the implantation of a peritoneal access port, 20 mg/m2 of ip PTX was administered weekly, in combination with mFOLFOX6-bevacizumab or CapeOX-bevacizumab. Primary endpoint was the safety of the combination chemotherapy.

Results

Among the six patients enrolled, three received the mFOLFOX6-bevacizumab plus ip PTX regimen and three received the CapeOX-bevacizumab plus ip PTX regimen. Dose-limiting toxicity was not observed. Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66.7%) for each chemotherapeutic regimen, but no grade 4 adverse events were observed. Moreover, adverse events associated with the peritoneal access port, such as infection or occlusion of the catheter, were not observed.

Conclusions

The adverse events of mFOLFOX6-bevacizumab or CapeOX-bevacizumab in combination with ip PTX were considered similar to those described in previous studies of oxaliplatin-based treatment alone. 1 year after the start of chemotherapy, the efficacy of ip PTX will be evaluated as a secondary outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545–1550

    Article  CAS  Google Scholar 

  2. Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34

    Article  PubMed  Google Scholar 

  3. Franko J, Shi Q, Goldman CD et al (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263–267

    Article  PubMed  Google Scholar 

  4. Franko J, Shi Q, Meyers JP et al (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 17:1709–1719

    Article  PubMed  Google Scholar 

  5. Murono K, Kawai K, Hata K et al (2018) Regimens of intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Anticancer Res 38:15–22

    CAS  PubMed  Google Scholar 

  6. Huang CQ, Min Y, Wang SY et al (2017) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 8:55657–55683

    PubMed  PubMed Central  Google Scholar 

  7. Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  8. Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68

    Article  PubMed  Google Scholar 

  9. Quenet F, Goere D, Mehta SS et al (2011) Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 254:294–301

    Article  PubMed  Google Scholar 

  10. Cashin PH, Mahteme H, Spang N et al (2016) Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 53:155–162

    Article  CAS  PubMed  Google Scholar 

  11. Markman M, Rowinsky E, Hakes T et al (1992) Phase I trial of intraperitoneal taxol: a gynecologic oncology group study. J Clin Oncol 10:1485–1491

    Article  CAS  PubMed  Google Scholar 

  12. Ishigami H, Kitayama J, Otani K et al (2009) Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 76:311–314

    Article  CAS  PubMed  Google Scholar 

  13. Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T (2013) A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 119:3354–3358

    Article  CAS  PubMed  Google Scholar 

  14. Takahara N, Isayama H, Nakai Y et al (2016) Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Investig New Drugs 34:636–642

    Article  CAS  Google Scholar 

  15. Satoi S, Fujii T, Yanagimoto H et al (2017) Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg 265:397–401

    Article  PubMed  Google Scholar 

  16. Ishigami H, Fujiwara Y, Fukushima R et al (2018) Phase III Trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC Trial. J Clin Oncol 36(19):1922–1929

    Article  CAS  PubMed  Google Scholar 

  17. Hribaschek A, Meyer F, Schneider-Stock R, Pross M, Ridwelski K, Lippert H (2007) Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy 53:410–417

    Article  CAS  PubMed  Google Scholar 

  18. Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374

    Article  CAS  Google Scholar 

  19. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  CAS  Google Scholar 

  20. Doi T, Boku N, Kato K et al (2010) Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 40:913–920

    Article  PubMed  PubMed Central  Google Scholar 

  21. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

    Article  CAS  Google Scholar 

  22. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  23. Cassidy J, Clarke S, Diaz-Rubio E et al (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105:58–64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. de Gramont A, Van Cutsem E, Schmoll HJ et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13:1225–1233

    Article  CAS  Google Scholar 

  25. Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278–1286

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research is supported by Grants-in-Aid for Scientific Research (C: Grant number; 16K07143, C: Grant number; 16K07161, C: Grant number; 17K10620, C: Grant number; 17K10621, C: Grant number; 17K10623 and C: Grant number; 18K07194) from Japan Society for the promotion of Science. This research is supported by the Project for Cancer Research and Therapeutic Evolution (P-CREATE, grant number: 18 cm0106502h0003 from the Japan Agency for Medical Research and Development (AMED).

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Koji Murono, Hiroshi Nagata, Kazuhiro Ishimaru, Shigenobu Emoto, Manabu Kaneko, Masaya Hiyoshi, Kazuhito Sasaki, Kensuke Otani, Yasutaka Shuno, Takeshi Nishikawa, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa & Soichiro Ishihara

  2. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

    Kei Muro

Authors
  1. Koji Murono
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Ishimaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigenobu Emoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manabu Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaya Hiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhito Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kensuke Otani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasutaka Shuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshiaki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Keisuke Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazushige Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hiroaki Nozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kei Muro
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Soichiro Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Murono.

Ethics declarations

Conflict of interest

K. Muro is on the advisory board meeting for Bristol-Myers Squibb and Nippon Kayaku Co, Ltd. All remaining authors have declared no conflicts of interest.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee of the University of Tokyo (P2015038-11X) and with the 1964 Helsinki declaration and its later amendments. The study was registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) (UNIN000022924).

Informed consent

Written informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murono, K., Nagata, H., Ishimaru, K. et al. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. Cancer Chemother Pharmacol 83, 145–150 (2019). https://doi.org/10.1007/s00280-018-3714-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3714-5

Keywords

Search

Navigation